{
    "id": 1661,
    "fullName": "DDR2 I638F",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "DDR2 I638F lies within the protein kinase domain of the Ddr2 protein (UniProt.org). I638F confers a gain of function to the Ddr2 protein, as demonstrated by increased Ddr2 phosphorylation (PMID: 28161936) and Stat5 activation and transformation of cultured cells, and induced tumor formation in mouse xenograft models (PMID: 22328973).",
            "references": [
                {
                    "id": 10579,
                    "pubMedId": 28161936,
                    "title": "Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28161936"
                },
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4921,
        "geneSymbol": "DDR2",
        "terms": [
            "DDR2",
            "MIG20a",
            "NTRKR3",
            "TKT",
            "TYRO10",
            "WRCN"
        ]
    },
    "variant": "I638F",
    "createDate": "09/10/2014",
    "updateDate": "07/24/2019",
    "referenceTranscriptCoordinates": {
        "id": 147393,
        "transcript": "NM_001014796",
        "gDna": "chr1:g.162775707A>T",
        "cDna": "c.1912A>T",
        "protein": "p.I638F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1804,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 I638F resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 3454,
                "profileName": "DDR2 I638F DDR2 T654M"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5121,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 I638F in culture, with increased potency over either agent alone (PMID: 22328973).",
            "molecularProfile": {
                "id": 3455,
                "profileName": "DDR2 I638F"
            },
            "therapy": {
                "id": 3756,
                "therapyName": "Nilotinib + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5103,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 I638F in culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 3455,
                "profileName": "DDR2 I638F"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1805,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell carcinoma cell line harboring a DDR2 I638F mutation in culture and in xenograft models (PMID: 22328973).",
            "molecularProfile": {
                "id": 3455,
                "profileName": "DDR2 I638F"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5102,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 I638F in culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 3455,
                "profileName": "DDR2 I638F"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1806,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of lung squamous cell carcinoma cells harboring a DDR2 I638F mutation in cell culture (PMID: 22328973).",
            "molecularProfile": {
                "id": 3455,
                "profileName": "DDR2 I638F"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 141,
                    "pubMedId": 22328973,
                    "title": "Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22328973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3454,
            "profileName": "DDR2 I638F DDR2 T654M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3455,
            "profileName": "DDR2 I638F",
            "profileTreatmentApproaches": [
                {
                    "id": 1221,
                    "name": "DDR2 inhibitor",
                    "profileName": "DDR2 I638F"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 147392,
            "transcript": "XM_011509587",
            "gDna": "chr1:g.162775707A>T",
            "cDna": "c.1912A>T",
            "protein": "p.I638F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 147390,
            "transcript": "XM_006711344",
            "gDna": "chr1:g.162775707A>T",
            "cDna": "c.1912A>T",
            "protein": "p.I638F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 147393,
            "transcript": "NM_001014796",
            "gDna": "chr1:g.162775707A>T",
            "cDna": "c.1912A>T",
            "protein": "p.I638F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 147391,
            "transcript": "XM_011509586",
            "gDna": "chr1:g.162775707A>T",
            "cDna": "c.1912A>T",
            "protein": "p.I638F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 147394,
            "transcript": "NM_006182",
            "gDna": "chr1:g.162775707A>T",
            "cDna": "c.1912A>T",
            "protein": "p.I638F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}